The stock of Blackmores Limited (ASX:BKL) hit a new 52-week low and has $103.02 target or 8.00% below today’s $111.98 share price. The 5 months bearish chart indicates high risk for the $1.93 billion company. The 1-year low was reported on Oct, 19 by Barchart.com. If the $103.02 price target is reached, the company will be worth $154.40M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 0.81% or $0.91 on October 19, hitting $111.98. About 271,589 shares traded hands or 97.21% up from the average. Blackmores Limited (ASX:BKL) has declined 36.55% since March 23, 2016 and is downtrending. It has underperformed by 42.09% the S&P500.
More notable recent Blackmores Limited (ASX:BKL) news were published by: Fool.com.Au which released: “Is the Blackmores Limited share price set to crash below $100?” on October 18, 2016, also Fool.com.Au with their article: “Blackmores Limited moves into Iran: Are the shares a buy?” published on September 28, 2016, Fool.com.Au published: “Why I’m excited by Blackmores Limited 46% share price fall in 2016” on September 12, 2016. More interesting news about Blackmores Limited (ASX:BKL) were released by: Fool.com.Au and their article: “Is Blackmores Limited a buy at $120?” published on September 01, 2016 as well as Fool.com.Au‘s news article titled: “Could Blackmores Limited fall back below $100?” with publication date: August 25, 2016.
Blackmores Limited is engaged in the development, sales and marketing of health products for humans and animals, including vitamins, herbal and mineral nutritional supplements. The company has a market cap of $1.93 billion. The Company’s divisions include Australia, China , Other Asia, BioCeuticals and Other. It has a 19.45 P/E ratio. The Firm offers over 250 vitamins, minerals, herbal and nutritional supplements.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.